Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials

Randomized controlled trial published in Circ Cardiovasc Interv (2016)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Randomized controlled trialDesarrollo de fármacosEnsayos clínicosDangas GD et al. · Circ Cardiovasc Interv, 2016

Abstract

BACKGROUND: Early stent thrombosis (ST) within 30 days after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction is a serious event. We sought to determine the predictors of and risk of mortality after early ST according to procedural antithrombotic therapy. METHODS AND RESULTS: In a patient-level pooled analysis from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trials, we examined 30-day outcomes in 4935 patients undergoing primary percutaneous coronary intervention with stent implantation at 188 international sites, randomized to either bivalirudin or heparin±a glycoprotein IIb/IIIa inhibitor (GPI). Early ST occurred in 100 patients (2.0%), 20 of whom (20.0%) died. Bivalirudin was associated with higher rates of early ST compared with heparin±GPI (2.5% versus 1.6%, P=0.04), because of more acute (≤24 h) ST (1.5% versus 0.2%, P<0.0001), with the risk limited to the first 4 hours after percutaneous coronary intervention. The rates of subacute (1-30 days) ST were similar with bivalirudin and heparin±GPI (1.0% versus 1.4%, P=0.24). Among patients with early ST, mortality within 30 days occurred in 4 of 60 (6.7%) bivalirudin-treated patients compared with 16 of 40 (40.0%) heparin±GPI-treated patients (adjusted hazard ratio, 0.12; 95% CI, 0.04-0.39; P=0.0004 and adjusted hazard ratio, 0.122; 95% CI, 0.04-0.39; P=0. 0004). Thus, 30-day mortality attributable to early ST occurred in 4 of 2479 (0.2%) bivalirudin-treated patients versus 16 of 2456 (0.7%) heparin±GPI-treated patients (P=0.007). CONCLUSIONS: In the present large-scale pooled analysis from 2 multicenter randomized trials, early ST was more frequent in patients treated with bivalirudin compared with heparin±GPI because of increased ST within 4 hours after primary percutaneous coronary intervention. However, the mortality attributable to early ST was significantly lower after bivalirudin than after heparin±GPI. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00433966 (HORIZONS-AMI) and NCT01087723 (EUROMAX).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov't

Indexed MeSH termsAgedBlood Vessel Prosthesis ImplantationElectrocardiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPatient Outcome AssessmentPeptide Fragments

Resumen

Early stent thrombosis (ST) within 30 days after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction is a serious event.

Por qué esto importa para la hirudoterapia

This patient-level pooled analysis from the HORIZONS-AMI and EUROMAX randomized trials (4,935 patients) examined early stent thrombosis and associated mortality after primary PCI for STEMI, comparing bivalirudin versus heparin with or without a glycoprotein IIb/IIIa inhibitor. Bivalirudin was associated with higher early stent thrombosis rates (2.5% vs 1.6%), driven by acute stent thrombosis within the first four hours, but mortality attributable to early stent thrombosis was significantly lower with bivalirudin (0.2% vs 0.7%). The abstract contains no mention of leeches, hirudotherapy, hirudin, or leech-secretome components. CAVEAT: This is a pooled analysis of randomized trials in interventional cardiology; no direct connection to ASH's domain can be established from the abstract alone.

Citación

Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.

Dangas GD et al. · Circ Cardiovasc Interv, 2016

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Hirudin Anticoagulation Compounds Hemostasis Cardiovascular Cardiology Dermatological Applications Dermatology Otolaryngology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026